Study Details
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors
Clinicaltrials.gov ID
Astellas Study ID
1650-CL-0201
EudraCT ID
N/A
Condition
Germ Cell Tumors, Advanced/Metastatic Cancer
Phase
Phase 2
Age
18 Years - N/A
Sex
Male
Product
N/A
Type
Interventional
Trial Dates
Mar 2019 - Oct 2020
Masking
None (Open Label)
Enrollment number
19
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Indiana University Simon Cancer Center
Indianapolis, United States, 46202
Abramson Cancer Center University of Pennsylvania
Philadelphia, United States, 19104
Memorial Sloan-Kettering Cancer Center
New York, United States, 10065